MedTrace Logo

Clinical Outcome of Vinpocetine in Diabetic Nephropathy

NCT06441591 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-07-11

No results posted yet for this study

Summary

The goal of this controlled, randomized, clinical trial is to evaluate the effect of vinpocetine on clinical outcomes on the diabetic nephropathy patients.

The following will be evaluated; anthropometrics, kidney functions, glucose panel, lipid panel, ICAM-1, quality of life.

Participants will receive either vinpocetine or placebo, twice daily for 3 months.

Conditions

  • Diabetic Kidney Disease
  • Diabetic Nephropathies

Interventions

DRUG

Vinpocetine

Vinca derivative of apovincamine, phosphodiestrase 1 inhibitor, sodium-gated voltage channel

DRUG

Standard Therapy

Anti-hypertensive and anti-diabetic medications according to the the institution's protocol

OTHER

Placebo

Starch-filled capsules, matching those of the intervention

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-10
Primary Completion
2025-06-01
Completion
2025-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06441591 on ClinicalTrials.gov